close read more

Servier launches its first scientific challenge with Innocentive


Servier launches its first scientific challenge with Innocentive

On November 6th, Servier launches its first scientific challenge in the field of neurodegenerative diseases, using the crowdsourcing platform Innocentive.

Innocentive is a website on which Research and Development teams share their problems, in the form of challenges, with a network of over 380 000 Solvers spread across nearly 200 countries. Solvers can then propose quick and innovative solutions to try to tackle those problems, which are evaluated by the team responsible for the challenge. Prizes are awarded for the best proposals.

Calling on collaborative effort

This innovative and collaborative approach is based on the concept of crowdsourcing, in that it calls on a collaborative effort to solve a specific problem. One of its particularities is that people who are not experts in the field or who come from very different research sectors are called upon to participate, in order to help find novel ideas.

Following several successful inhouse crowdsourcing initiatives, including a challenge in phlebology to optimise the management of venous diseases, which generated 207 ideas from 37 countries and led to the creation of 10 projects, we are continuing on this trajectory with the launch of our first challenge on Innocentive, which is open to the entire world and this time devoted to neurodegenerative diseases.

Highly committed in this field, our Group seeks to deepen its understanding of certain interactions between proteins in the brain, particularly those thought to be responsible for conditions such as Alzheimer’s disease and Parkinson’s disease. With this challenge, we hope to develop and accelerate our ongoing efforts to find new and effective treatments for neuropsychiatric diseases and, if possible, apply it to our other fields of expertise, in order to bring new therapeutic solutions to patients more quickly.

Last news

Meeting the challenge of adherence: a Servier study presented at the ESH 2022 Annual Meeting!
Appointment of Angelo Paci, Oncology & Immuno-Oncology Program Leader
Patient associations’ perception of pharmaceutical companies: Servier is making progress!